New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:41 EDTTHOR, HTWRCorrection: Thoratec attractive on any post-guidance weakness, says Oppenheimer
Oppenheimer reports that Thoratec (THOR) will provide 2013 guidance on February 5, and the firm adds that the company has traditionally been conservative with its first outlook of the year. Oppenheimer thinks the stock may be muted in the near-term but it believes that the shares will have a number of positive catalysts later in the year. It recommends buying the shares on any pullbacks. A previous note incorrectly stated that this note from Oppenheimer was written about HeartWare (HTWR).
News For THOR;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:29 EDTHTWR, THORCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
07:26 EDTHTWRHeartWare weakness a buying opportunity, says Canaccord
Subscribe for More Information
April 17, 2015
07:58 EDTTHORThoratec to hold an investor and analyst meeting
Subscribe for More Information
05:35 EDTTHORThoratec announces positive results from ROADMAP study
Thoratec announced results from the ROADMAP Study, or the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference.
April 16, 2015
10:04 EDTTHORHigh option volume stocks
Subscribe for More Information
09:52 EDTHTWR, THORThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTTHOR, HTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 14, 2015
10:03 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
April 11, 2015
14:10 EDTTHOR, HTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use